Form 4: Cue Biopharma Director, Patrick Verheyen, Awarded Stock Options

Patrick Verheyen, a director at Cue Biopharma, was granted stock options for 24,400 shares on January 2, 2025.

Summary

• This document is a Form 4 filing with the SEC, reporting a change in beneficial ownership for Patrick Verheyen, a director at Cue Biopharma, Inc.
• On January 2, 2025, Verheyen was granted a stock option to purchase 24,400 shares of Cue Biopharma's common stock at an exercise price of $1.09 per share.
• The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the first anniversary.
• The options expire on January 1, 2035.
• Following the transaction, Verheyen directly owns options for 24,400 shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that a director is incentivized to contribute to the company's success.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for at least one year.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to increase shareholder value through their work at the company.

Key Dates